journal article·2018-04-25Open access

Interleukin-6 Neutralization by Antibodies Immobilized at the Surface of Polymeric Nanoparticles as a Therapeutic Strategy for Arthritic Diseases

Ana Cláudia Lima, Cristina Cunha, Agostinho Carvalho, Helena Ferreira, Nuno M. Neves

ACS Applied Materials & Interfaces· Volume 10· Issue 16

Abstract

Arthritic diseases are disabling conditions affecting millions of patients worldwide. Pro-inflammatory cytokines, particularly interleukin-6 (IL-6), plays a crucial role in inflammation and cartilage destruction. Although the beneficial effects of antibody therapy, its efficacy is limited. Therefore, this work proposes the immobilization of antibodies at the surface of biodegradable polymeric nanoparticles (NPs) to capture and neutralize IL-6. Our system is intended to protect, extend and enhance the therapeutic efficacy after delivery. Chitosan-hyaluronic acid NPs are synthesized as a stable monodisperse population. After determining the maximum immobilization capacity (10 μg/mL), the capture ability was confirmed. Biological assays demonstrate the NPs cytocompatibility with human articular chondrocytes (hACs) and human macrophages. hACs stimulated with macrophage conditioned medium shows the beneficial role of IL-6 capture and neutralization. Biofunctionalized NPs exhibit a prolonged action and stronger efficacy than the free antibody. In conclusion, this system can be an effective and long lasting treatment for arthritic diseases.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Monoclonal and Polyclonal Antibodies Research · RNA Interference and Gene Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

3B’s Research Group—Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, AvePark, 4805-017 Barco, Guimarães, Portugal

ICVS/3B’s—PT Government Associate Laboratory, 4805-017 Braga/Guimarães, Portugal

Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal

The Discoveries Centre for Regenerative and Precision Medicine, Headquarters at University of Minho, Avepark 4805-017 Barco, Guimarães, Portugal

Funding

European Regional Development Fund · Funda??o para a Ci?ncia e a Tecnologia

References (44)

Show source-provided references
1. 10.2147/IJN.S8915610.2147/IJN.S89156 ↗
2. Woolf A. D. · Bull. World Health Organ. · 2003 · 81 · 646
3. 10.1038/nrrheum.2015.9510.1038/nrrheum.2015.95 ↗
4. 10.1016/j.bone.2011.10.00810.1016/j.bone.2011.10.008 ↗
5. 10.1016/j.bcp.2010.02.01710.1016/j.bcp.2010.02.017 ↗
6. 10.1002/eji.20104039110.1002/eji.201040391 ↗
7. 10.1186/s12891-015-0516-310.1186/s12891-015-0516-3 ↗
8. 10.1021/acsami.7b1075310.1021/acsami.7b10753 ↗
9. 10.1002/art.2459810.1002/art.24598 ↗
10. 10.2174/13816120878424607210.2174/138161208784246072 ↗
11. 10.4172/2161-1149.S4-00210.4172/2161-1149.S4-002 ↗
12. 10.1038/nrrheum.2011.14510.1038/nrrheum.2011.145 ↗
13. 10.2165/11539760-000000000-0000010.2165/11539760-000000000-00000 ↗
14. 10.2174/092986732366616053014444510.2174/0929867323666160530144445 ↗
15. 10.1002/wnan.136410.1002/wnan.1364 ↗
16. 10.1016/j.colsurfb.2009.09.00110.1016/j.colsurfb.2009.09.001 ↗
17. 10.1002/marc.20140040610.1002/marc.201400406 ↗
18. 10.1021/bm500346s10.1021/bm500346s ↗
19. 10.1016/j.carbpol.2012.04.05710.1016/j.carbpol.2012.04.057 ↗
20. 10.1002/jbm.a.3246610.1002/jbm.a.32466 ↗
21. 10.1016/j.immuni.2016.02.00410.1016/j.immuni.2016.02.004 ↗
22. 10.1016/j.ijbiomac.2017.01.04210.1016/j.ijbiomac.2017.01.042 ↗
23. 10.1016/j.ijpharm.2014.10.02310.1016/j.ijpharm.2014.10.023 ↗
24. Litwiniuk M. · Wounds: A Compendium of Clinical Research and Practice · 2016 · 28 · 78
25. 10.1016/j.ijpharm.2013.07.01710.1016/j.ijpharm.2013.07.017 ↗
26. 10.1002/term.181210.1002/term.1812 ↗
27. 10.1167/iovs.07-107710.1167/iovs.07-1077 ↗
28. 10.1016/j.ijpharm.2011.08.04610.1016/j.ijpharm.2011.08.046 ↗
29. 10.1016/S0142-9612(98)00036-210.1016/S0142-9612(98)00036-2 ↗
30. 10.1021/acs.chemrev.5b0029010.1021/acs.chemrev.5b00290 ↗
31. 10.1016/j.biomaterials.2014.08.04210.1016/j.biomaterials.2014.08.042 ↗
32. 10.1039/C6RA13713J10.1039/C6RA13713J ↗
33. 10.1093/rb/rbv00510.1093/rb/rbv005 ↗
34. 10.1016/j.jconrel.2013.08.00610.1016/j.jconrel.2013.08.006 ↗
35. 10.1208/s12248-014-9579-610.1208/s12248-014-9579-6 ↗
36. 10.22203/eCM.v034a2110.22203/eCM.v034a21 ↗
37. 10.1007/s11095-012-0870-x10.1007/s11095-012-0870-x ↗
38. 10.1021/mp300182710.1021/mp3001827 ↗
39. 10.1016/j.jconrel.2016.06.01710.1016/j.jconrel.2016.06.017 ↗
40. 10.1186/ar329310.1186/ar3293 ↗
41. 10.1007/s00264-012-1724-110.1007/s00264-012-1724-1 ↗
42. 10.1155/2009/43938910.1155/2009/439389 ↗
43. 10.1111/ajt.1426610.1111/ajt.14266 ↗
44. 10.1007/s10439-016-1600-z10.1007/s10439-016-1600-z ↗